Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

J&J Secures Expanded TECVAYLI Approval for Multiple Myeloma Treatment

Guavy AI Editorial Team
Instruments
JNJ
Share

Johnson & Johnson's (NYSE:JNJ) European regulatory approval has expanded the role of TECVAYLI in multiple myeloma care, strengthening its established oncology portfolio.

The decision allows physicians to use the combination of TECVAYLI and daratumumab for adults with relapsed or refractory multiple myeloma, giving them another treatment approach.

This latest regulatory milestone reinforces Johnson & Johnson's strategy centered on specialized medicines addressing serious diseases where treatment needs remain significant.

More on Stocks

Stocks just now

Disney Teams Up with NFL for Character-Driven Fashion Collection

Stocks 1m ago

Disney+ Brings College Football Saturdays to Subscribers

Stocks 2m ago

Super Micro Stock Soars on Cisco Partnership and Taiwan Clearance

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy